Nakayama et al. [91] further analyzed CDKN2A/p16 hypermethylation as a marker for CRC recurrence; 8 out of 21 CRC detected p16 hypermethylation in preoperative serum samples and 13 out of 21 CRC detected p16 hypermethylation in primary tumor biopsies suggesting its potential role in recurrence of CRC. The gene discussed is CDKN2A; the disease is neoplasm.